{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:51:12Z","timestamp":1790812272526,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.tcm.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T22:39:06Z","timestamp":1552948746000},"page":"80-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis"],"prefix":"10.1016","volume":"30","author":[{"given":"Vadzim","family":"Chyzhyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-2821","authenticated-orcid":false,"given":"Alan S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tcm.2019.03.001_bib0001","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jacl.2018.02.018","article-title":"Roundtable discussion: familial chylomicronemia syndrome: diagnosis and management","volume":"12","author":"Brown","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.tcm.2019.03.001_bib0002","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14779072.2017.1311786","article-title":"The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study","volume":"15","author":"Davidson","year":"2017","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"6","key":"10.1016\/j.tcm.2019.03.001_bib0003","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u2013current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.tcm.2019.03.001_bib0004","first-page":"891","article-title":"Classification of hyperlipidaemias and hyperlipoproteinaemias","volume":"43","author":"Beaumont","year":"1970","journal-title":"Bull World Health Organ"},{"issue":"8","key":"10.1016\/j.tcm.2019.03.001_bib0005","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.tcm.2019.03.001_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5551\/jat.10702","article-title":"Diagnosis and management of type I and type V hyperlipoproteinemia","volume":"19","author":"Gotoda","year":"2012","journal-title":"J Atheroscler Thromb"},{"issue":"12","key":"10.1016\/j.tcm.2019.03.001_bib0007","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/13543784.2016.1254187","article-title":"Lomitapide for the treatment of hypertriglyceridemia","volume":"25","author":"Brahm","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.tcm.2019.03.001_bib0008","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.atherosclerosis.2015.04.815","article-title":"Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia","volume":"241","author":"Rabacchi","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tcm.2019.03.001_bib0009","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.tcm.2019.03.001_bib0010","first-page":"249","article-title":"Chylomicronemia syndrome","volume":"37","author":"Chait","year":"1992","journal-title":"Adv Intern Med"},{"key":"10.1016\/j.tcm.2019.03.001_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","article-title":"Diagnostic algorithm for familial chylomicronemia syndrome","volume":"23","author":"Stroes","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.tcm.2019.03.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-212587","article-title":"Lipoprotein lipase deficiency presenting with neonatal perianal abscesses","volume":"2016","author":"Akesson","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"8","key":"10.1016\/j.tcm.2019.03.001_bib0013","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","article-title":"Current knowledge of hypertriglyceridemic pancreatitis","volume":"25","author":"Valdivielso","year":"2014","journal-title":"Eur J Int Med"},{"issue":"8","key":"10.1016\/j.tcm.2019.03.001_bib0014","doi-asserted-by":"crossref","first-page":"e72146","DOI":"10.1371\/journal.pone.0072146","article-title":"Comparative analyses of lipoprotein lipase, hepatic lipase, and endothelial lipase, and their binding properties with known inhibitors","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One."},{"issue":"5","key":"10.1016\/j.tcm.2019.03.001_bib0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1101\/gad.209296.112","article-title":"Biochemistry and pathophysiology of intravascular and intracellular lipolysis","volume":"27","author":"Young","year":"2013","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/j.tcm.2019.03.001_bib0016","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jacl.2017.05.017","article-title":"GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia","volume":"11","author":"Hu","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"17","key":"10.1016\/j.tcm.2019.03.001_bib0017","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1611930","article-title":"Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia","volume":"376","author":"Beigneux","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.tcm.2019.03.001_bib0018","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/jpet.115.229740","article-title":"Creation of Apolipoprotein C-II (ApoC-II) mutant mice and correction of their hypertriglyceridemia with an ApoC-II mimetic peptide","volume":"356","author":"Sakurai","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.tcm.2019.03.001_bib0019","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1210\/jc.2016-3903","article-title":"A Novel APOC2 missense mutation causing Apolipoprotein C-II deficiency with severe triglyceridemia and pancreatitis","volume":"102","author":"Ueda","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.tcm.2019.03.001_bib0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1373\/clinchem.2004.044826","article-title":"Apolipoprotein A5 and hypertriglyceridemia","volume":"51","author":"Charlton-Menys","year":"2005","journal-title":"Clin Chem."},{"issue":"5","key":"10.1016\/j.tcm.2019.03.001_bib0021","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of Apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.tcm.2019.03.001_bib0022","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/MOL.0000000000000281","article-title":"Novel therapies for severe dyslipidemia originating from human genetics","volume":"27","author":"Gaudet","year":"2016","journal-title":"Curr Opin Lipidol"},{"issue":"11","key":"10.1016\/j.tcm.2019.03.001_bib0023","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1089\/hum.2015.158","article-title":"Long-Term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis","volume":"27","author":"Gaudet","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"23","key":"10.1016\/j.tcm.2019.03.001_bib0024","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.tcm.2019.03.001_bib0025","first-page":"1837","article-title":"Total parenteral nutrition in a pregnant patient with acute pancreatitis and lipoprotein lipase deficiency","volume":"32","author":"Contreras-Bol\u00edvar","year":"2015","journal-title":"Nutr Hosp"},{"issue":"1","key":"10.1016\/j.tcm.2019.03.001_bib0026","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jca.20192","article-title":"Management of familial hypertriglyceridemia during pregnancy with plasma exchange","volume":"24","author":"Sivakumaran","year":"2009","journal-title":"J Clin Apher"},{"issue":"1","key":"10.1016\/j.tcm.2019.03.001_bib0027","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1475-2840-11-125","article-title":"Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction","volume":"11","author":"Tenenbaum","year":"2012","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.tcm.2019.03.001_bib0028","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11883-017-0697-3","article-title":"ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen","volume":"19","author":"Rocha","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.tcm.2019.03.001_bib0029","unstructured":"Document FDAB. FDA Briefing Document Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 2014:1\u201387."},{"issue":"2","key":"10.1016\/j.tcm.2019.03.001_bib0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacl.2014.12.006","article-title":"Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials","volume":"9","author":"Panta","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.tcm.2019.03.001_bib0031","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/MOL.0000000000000354","article-title":"New oral agents for treating dyslipidemia","volume":"27","author":"Gryn","year":"2016","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"10.1016\/j.tcm.2019.03.001_bib0032","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jacl.2015.03.065","article-title":"Pradigastat, a diacylglycerol acyltransferase 1 inhibitor, reduces fasting triglyceride levels in familial chylomicronemia","volume":"9","author":"Gaudet","year":"2015","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.tcm.2019.03.001_bib0033","doi-asserted-by":"crossref","unstructured":"Falko JM. Review Article familial chylomicronemia syndrome: aa clinical guide for endocrinologists. 2018. doi:10.4158\/EP-2018-0157.","DOI":"10.4158\/EP-2018-0157"},{"issue":"3","key":"10.1016\/j.tcm.2019.03.001_bib0034","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"NEJM"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173819300301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173819300301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:58:30Z","timestamp":1760936310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173819300301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1050173819300301"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2019.03.001","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}